Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 9-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 25)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 New Constructs, LLC N/A AIS: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
6-Feb-10 Reuters Investment Profile N/A Alternative Investment Strategies Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A Antares Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: AIS , APPA , CPRX , NLTX , NBY , PCYC , VRUS , DDD -- DRUGS 3 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: ANTARES PHARMA -- AIS 1 $4 View Abstract
4-Feb-10 Wright Reports N/A Wright Investors Service Comprehensive Report for Antares Pharma, Inc. 43 $65 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for AIS: the economy's impact on AIS's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ANTARES PHARMA INC 5 $25 View Abstract
26-Jan-10 Wall Street Transcript ,The The Wall St Transcript MANAGEMENT TURNOVER REPORT - Antares Pharma, Inc. (AIS) 6 $50 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ANTARES PHARMA INC 5 $25 View Abstract
Next 15

Brokerage Reports (Showing 1 to 2 of 2)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
8-Jan-10 Roth Capital Partners, Inc. Research Department Morning Call Summary 19 $50 View Abstract
8-Jan-10 Roth Capital Partners, Inc. Edward Nash A Drug Delivery Company That Is Delivering Results 22 $75 View Abstract

Independent Reports (Showing 1 to 10 of 23)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 New Constructs, LLC N/A AIS: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings 19 $10 View Abstract
6-Feb-10 Reuters Investment Profile N/A Alternative Investment Strategies Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
6-Feb-10 Reuters Investment Profile N/A Antares Pharma Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. 12 $20 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: AIS , APPA , CPRX , NLTX , NBY , PCYC , VRUS , DDD -- DRUGS 3 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: ANTARES PHARMA -- AIS 1 $4 View Abstract
4-Feb-10 Wright Reports N/A Wright Investors Service Comprehensive Report for Antares Pharma, Inc. 43 $65 View Abstract
2-Feb-10 EconomicInvestor N/A "The Economy Matters" Report for AIS: the economy's impact on AIS's price and risk, featuring the powerful EconomicInvestor Star Rating 6 $15 View Abstract
31-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ANTARES PHARMA INC 5 $25 View Abstract
26-Jan-10 Wall Street Transcript ,The The Wall St Transcript MANAGEMENT TURNOVER REPORT - Antares Pharma, Inc. (AIS) 6 $50 View Abstract
24-Jan-10 TheStreet.com Ratings N/A TheStreet.com Ratings Stock Report For: ANTARES PHARMA INC 5 $25 View Abstract
Next 13

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.